Followers | 49 |
Posts | 11680 |
Boards Moderated | 0 |
Alias Born | 06/15/2014 |
Monday, June 13, 2022 5:49:52 AM
“Not long after Sun bought Ranbaxy from Daiichi Sankyo in 2014 the Japanese company was hit with claims against the Indian generics giant. Ranbaxy was accused of falsely representing the quality of the drugs it made as well as its handling of compliance issues raised by the FDA. By making those false assertions, they were able to be first to file and win exclusivity — giving them an opportunity to charge more for the first knockoffs.
In 2013 Ranbaxy agreed to pay $500 million — $150 million to cover a criminal fine and forfeiture with $350 million for civil claims — related to felony charges for making and selling adulterated drugs. And in 2017 Sun shelled out $150 million to cover the last of the litigation sparked by a pay-for-delay case involving Ranbaxy.”
https://endpts.com/sun-pharma-shelling-out-485m-to-settle-us-antitrust-case-against-generics-giant/
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM